Efficacy and Safety of Quetiapine-XR as Monotherapy or Adjunctive Therapy to a Mood Stabilizer in Acute Bipolar Depression With Generalized Anxiety Disorder and Other Comorbidities: A Randomized, Placebo-Controlled Trial
The DOI matches its Crossref record.
Abstract
OBJECTIVE: To study the efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar I or II depression with comorbid generalized anxiety disorder (GAD) and other comorbidities. METHOD: The study was conducted from January 2007 to November 2011. The Mini-International Neuropsychiatric Interview was used to ascertain the diagnosis of DSM-IV bipolar disorder, GAD, and other Axis I disorders. Eligible patients were randomly assigned to quetiapine-XR or placebo for up to 8 weeks. The Hamilton Depression Rating Scale-17 items (HDRS-17) was used as a primary outcome to evaluate the difference between the 2 groups using the change from baseline to end of study. Last observation carried forward and mixed-effects modeling for repeated measures were used to analyze the primary and secondary outcome measures. RESULTS: Of the 120 patients screened, 100 patients were randomized to receive quetiapine-XR (n = 50) or placebo (n = 50). Twenty-six patients in the quetiapine-XR and 18 in the placebo group completed the study. The mean quetiapine-XR dose was 276 ± 50 mg/d (50-300 mg/d). There was no significant difference between the 2 groups in the change from baseline to end of study in HDRS-17 total score with an effect size of 0.19 favoring quetiapine-XR. There were also no significant differences between the 2 groups in secondary efficacy and safety outcome measures. CONCLUSIONS: Quetiapine-XR was not significantly superior to placebo in bipolar I or II depression with GAD and other comorbidities, suggesting that data from relatively "pure" bipolar patients may not be generalizable to a highly comorbid population. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00671853.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Quetiapine failed to provide any benefit in terms of mood and anxiety symptoms in a small subsample of highly comorbid patients with BD. generalized anxiety disorder (GAD) and cannabis use disorder701 (level 3 negative).”
In the citing paper
“No significant improvement was found in depressive or anxiety symptoms but alcohol or substance use‐related outcomes were not reported separately.”
Citations
Cites
Still being checked.
Cited by
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationVieta, E., Berk, M., Schulze, T. G., Carvalho, A. F., Suppes, T., Calabrese, J. R., Gao, K., Miskowiak, K. W., & Grande, I. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.8 · Cited by 891
Self-citationFountoulakis, K. N., Yatham, L., Grunze, H., Vieta, E., Young, A., Blier, P., Kasper, S., & Moeller, H. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw100 · Cited by 116
Prisciandaro, J. J., Tolliver, B. K., Prescot, A. P., Brenner, H. M., Renshaw, P. F., Brown, T. R., & Anton, R. F. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.141 · Cited by 80
Albert, U., Carmassi, C., Cosci, F., De Cori, D., Di Nicola, M., Ferrari, S., Poloni, N., Tarricone, I., & Fiorillo, A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000127 · Cited by 58
Pharmacotherapy of Bipolar Disorder with Quetiapine: A Recent Literature Review and an Update
Muneer, A. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.1.25 · Cited by 54
Treatment–resistant panic disorder: a systematic review
Freire, R. C., Zugliani, M. M., Garcia, R. F., & Nardi, A. E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1109628 · Cited by 47
“[10] Quetiapine showed anxiolytic properties in several studies and is used in mood disorders with good results,[34,35] for this reason quetiapine is also a promising agent for the treatment of PD and treatment–resistant PD.”
BackgroundThe Importance of Anxiety States in Bipolar Disorder
Goes, F. S. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-014-0540-2 · Cited by 39
Castro Santos, H., & Gama Marques, J. (2021) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000128 · Cited by 37
“Symptom remission was defined as ≥50% reduction from baseline scores plus a score of 7 on either GRIDHAMD or HAM-A.30,31 Fifteen secondary measures were also applied, including BDI,18 HADS22 and STAI.20 No serious adverse events were reported although some adverse events were registered.”
MethodPost, R. M., Altshuler, L. L., Kupka, R., McElroy, S. L., Frye, M. A., Rowe, M., Grunze, H., Suppes, T. M., Keck, P. E., Leverich, G. S., et al. (2015) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.14080204 · Cited by 36
The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders
Pignon, B., du Montcel, C. T., Carton, L., & Pélissolo, A. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0847-x · Cited by 35
Galling, B., Garcia, M. A., Osuchukwu, U., Hagi, K., & Correll, C. U. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1053457 · Cited by 27
Abejuela, H. R., & Osser, D. N. (2016) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000098 · Cited by 25
Garriga, M., Solé, E., González-Pinto, A. M., Selva‐Vera, G., Arranz, B., Amann, B. L., Sáiz-Ruiz, J., Pérez‐Blanco, J., & Vieta, E. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.429 · Cited by 25
Treatment of anxiety disorders in patients with comorbid bipolar disorder
Ott, C. A. (2018) · Mental Health Clinician · doi:10.9740/mhc.2018.11.256 · Cited by 24
Wang, D., & Osser, D. N. (2019) · Bipolar Disorders · doi:10.1111/bdi.12860 · Cited by 23
Jain, R., McIntyre, R. S., Cutler, A. J., Earley, W. R., Nguyen, H., Adams, J., & Yatham, L. N. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000500 · Cited by 20
Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale
Kinrys, G., Bowden, C. L., Nierenberg, A. A., Hearing, C. M., Gold, A. K., Rabideau, D. J., Sylvia, L. G., Gao, K., Kamali, M., Bobo, W. V., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.039 · Cited by 20
Self-citationGao, K., Ganocy, S. J., Conroy, C. M., Brownrigg, B., Serrano, M. B., & Calabrese, J. R. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4642-5 · Cited by 18
Self-citationCrapanzano, C., Damiani, S., & Guiot, C. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001420 · Cited by 16
Cullen, C., Kappelmann, N., Umer, M., Abdolizadeh, A., Husain, M. O., Bonato, S., Sharma, G. K., Xue, S., Ortiz, A., Kloiber, S. M., et al. (2021) · Bipolar Disorders · doi:10.1111/bdi.13125 · Cited by 16
Li, R., Wu, R., Chen, J., Kemp, D. E., Ren, M., Conroy, C. M., Chan, P., Serrano, M. B., Ganocy, S. J., Calabrese, J. R., et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4339 · Cited by 14
Self-citationThe use of antidepressants in bipolar disorder patients with depression
Bowden, C. L., & Singh, V. K. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1104299 · Cited by 10
Vatsalya, V., Pandey, A., Schwandt, M. L., Cave, M. C., Barve, S. S., Ramchandani, V. A., & McClain, C. J. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0439-2 · Cited by 10
Gao, K., Arnold, J. G., Prihoda, T. J., Quinones, M. P., Singh, V. K., Schinagle, M., Conroy, C. M., D’Arcangelo, N., Bai, Y., Calabrese, J. R., et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4604 · Cited by 10
Self-citationGoldberg, J. F., SIU, C. O., Tocco, M., Pikalov, A., & Loebel, A. D. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22m14732 · Cited by 8
Antipsychotiques : quand et comment les prescrire ?
Tebeka, S., Airagnes, G., & Limosin, F. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2016.12.007 · Cited by 9
The place of quetiapine extended release in the treatment of mental disorders
Styczeń, K., Datka, W., Jaeschke, R., Drozdowicz, K., Siwek, M., & Dudek, D. (2015) · Psychiatria Polska · doi:10.12740/pp/33909 · Cited by 4
Geerling, B., Kraiss, J. T., Kelders, S. M., Stevens, A. W. M. M., Kupka, R., & Bohlmeijer, E. T. (2019) · Bipolar Disorders · doi:10.1111/bdi.12746 · Cited by 4
Reichelt, L. (2020) · mediaTUM (Technical University of Munich) · Cited by 1
Pharmacological Treatment of Acute Bipolar Depression
Sachs, G. S. (2016) · Milestones in drug therapy · doi:10.1007/978-3-319-31689-5_9
Buckley, P. F., & Foster, A. E. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as28
Chapter 13. Pharmacotherapy for Generalized Anxiety Disorder
Ameringen, M. V., Patterson, B. A., Dabas, G., Sharpe, I., & Marrello, D. (2020) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379378.lg13
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Figshare · doi:10.25384/sage.13228182
Metadata
- Authors
- Gao, K., Wu, R., Kemp, D. E., Chen, J., Karberg, E., Conroy, C., Chan, P., Ren, M., Serrano, M. B., Ganocy, S. J., & Calabrese, J. R.
- Affiliations
- University Hospitals Cleveland Medical Center (US)
- Central South University (CN)
- Shanghai Jiao Tong University (CN)
- Case Western Reserve University (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-06-24
- Volume
- 75
- Issue
- 10
- Pages
- 1062-1068
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1980958940
- Cited by
- 29
- References
- 0
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 1 · 2021: 3 · 2019: 1 · 2018: 4 · 2017: 5 · 2016: 5 · 2015: 7
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- bipolar depression, generalized anxiety disorder, comorbidities, adjunctive therapy, mood stabilizers, monotherapy, atypical antipsychotics, treatment efficacy, drug safety
- MeSH terms
- Quetiapine Fumarate, Acute Disease, Adult, Anxiety Disorders, Bipolar Disorder, Delayed-Action Preparations, Dibenzothiazepines, Double-Blind Method, Drug Synergism, Female, Humans, Male, Middle Aged, Placebos, Antipsychotic Agents, Comorbidity, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.